

Appl. No. 09/124,485

Proposed Amdt. Dated October 15, 2003 in response to Office Action Of June 2, 2003

Amendments to the Claims:

BEST AVAILABLE COPY

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-26 (canceled)

27-33 (withdrawn)

34-37 (canceled)

38. (currently amended) A method for the prophylaxis or treatment of infection by a *Plasmodium* species in a non-rodent mammal, said method comprising administering to said non-rodent mammal an agent that increases nitric oxide levels, ~~production or delivery, thereby killing, inhibiting, or otherwise retarding the growth, infectivity or pathogenesis of the *Plasmodium* species.~~
39. (previously amended) A method according to claim 38 wherein the non-rodent mammal is a human.
40. (previously amended) A method according to claim 46 wherein the *Plasmodium* species is *Plasmodium falciparum*.
41. (currently amended) A method according to claim 38 wherein the agent is administered by inhalation, ~~to increase systemic nitric oxide levels or nitric oxide effect.~~
42. (previously amended) A method according to claim 38 wherein the agent is a nitric oxide (NO) donor.

BEST AVAILABLE COPY

Appl. No. 09/124,485

Proposed Amdt. Dated October 15, 2003 in response to Office Action Of June 2, 2003

43. (previously amended) A method according to claim 38 wherein the agent results in the formation within the circulatory system of nitric oxide in the form of a compound of formula:



Wherein R is an NO releasing, delivering or transferring moiety selected from the group consisting of an amino acid, peptide, polypeptide, protein, enzyme, amine, glycolipid, polysaccharide and a chemical derivative thereof.

44. (canceled)

45. (previously amended) A method according to claim 38 wherein the agent is selected from the group consisting of cysteinylglycine, cysteine, cysteamine, lipoic acid, dithiothreitol, glutathione, L-arginine, penicillamine, N-acetyl-penicillamine, N-acetylcysteine, albumin, tissue plasminogen activator, streptokinase, a cytokine, an antagonist or agonist of a cytokine, interferon (IFN) $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IFN $\delta$ , granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), an interleukin (IL) 1 to IL13, hemoglobin and cathepsin B.

46. (previously added) A method according to claim 38, wherein the *Plasmodium* species is selected from the group consisting of *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium ovale*, and *Plasmodium malariae*.

**BEST AVAILABLE COPY**

Appl. No. 09/124,485

Proposed Amdt. Dated October 15, 2003 in response to Office Action Of June 2, 2003

47. (previously added) A method according to claim 38 wherein the agent results in the formation within the tissues of nitric oxide in the form of a compound of formula:



Wherein R is an NO releasing, delivering or transferring moiety selected from the group consisting of an amino acid, peptide, polypeptide, protein, enzyme, amine, glycolipid, polysaccharide and a chemical derivative thereof.